Compare BHST & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHST | OVID |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.1M | 116.8M |
| IPO Year | N/A | 2017 |
| Metric | BHST | OVID |
|---|---|---|
| Price | $5.30 | $1.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $14.00 | $3.50 |
| AVG Volume (30 Days) | 61.8K | ★ 1.5M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,720,000.00 | $6,610,000.00 |
| Revenue This Year | $116.40 | $1,077.56 |
| Revenue Next Year | $55.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 45.88 | ★ 945.89 |
| 52 Week Low | $4.72 | $0.24 |
| 52 Week High | $12.80 | $2.01 |
| Indicator | BHST | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 56.11 |
| Support Level | $5.07 | $1.59 |
| Resistance Level | $5.43 | $1.88 |
| Average True Range (ATR) | 0.43 | 0.13 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 23.36 | 73.39 |
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.